Information Provided By: 
Fly News Breaks for August 8, 2018
RIGL
Aug 8, 2018 | 20:38 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Rigel Pharmaceuticals, saying the company's Q2 earnings report also indicated a "highly encouraging initial update on the Tavalisse launch". Citing the drug's "relatively low payer snag, limited need for free drug, and encouraging mix of later and earlier stage patient", the analyst contends that the program is off to a "great start", maintaining his sales model of over $200M by 2022 and over $300M by 2025.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
